Abbott Launches Over-the-Counter Continuous Glucose Monitoring System

By Sneha S K
Reuters

Abbott has launched its over-the-counter continuous glucose monitoring system, called Lingo, in the U.S. This device is the second of its kind to hit the market, allowing users to track their blood sugar levels.

Competition and Market Expansion

Lingo competes with a recent product from DexCom, which was launched the previous week. The device is targeted at adults not using insulin. Continuous glucose monitors are seeing a significant demand, primarily from diabetes patients, leading companies to target health-conscious consumers as well.

Olivier Ropars, head of Abbott’s Lingo business, noted a growing interest in tracking health-related biomarkers that were previously undetectable with existing consumer trackers.

Device Features

The continuous glucose monitoring system consists of coin-sized adhesive skin patches that connect via Bluetooth to a smartphone, eliminating the need for fingerstick blood samples. This tool helps diabetic patients determine if they need an insulin dose.

Pricing and Availability

Lingo is available for individuals aged 18 and older who are not using insulin. There are three pricing options:
– $49 for two weeks
– $89 for four weeks
– $249 for twelve weeks

Each biosensor can be worn for up to two weeks. Conversely, Dexcom’s Stelo costs up to $99 for two sensors or $89 for a four-week subscription.

Abbott received clearance from U.S. health regulators for Lingo, which has been available in Britain since January for £120-150 (approximately $152-$190) per month. Abbott’s CEO, Robert Ford, announced plans to employ TV advertisements and guerrilla marketing to attract consumers without diabetes during the U.S. launch.